|
APAS Presented at ASM Conference
|
20 June 2023 at 10:30am
|
|
APAS Compact Extension to Project Funding Timeframe
|
20 June 2023 at 10:30am
|
|
Notice under Section 708A - Cleansing Notice
|
2 June 2023 at 10:20am
|
|
Application for quotation of securities - LBT
|
2 June 2023 at 8:40am
|
|
Notice under Section 708A - Cleansing Notice
|
26 May 2023 at 2:10pm
|
|
Application for quotation of securities - LBT
|
26 May 2023 at 8:45am
|
|
New Company Presentation
|
12 May 2023 at 9:10am
|
|
Upcoming Investor Webinar Presentation
|
10 May 2023 at 9:15am
|
|
LBT Board - Chair Transition Process
|
8 May 2023 at 10:30am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2023 at 9:10am
|
|
NEW APAS-AMR DATA PRESENTED AT GLOBAL CONFERENCE
|
19 April 2023 at 10:30am
|
|
Notification of cessation of securities - LBT
|
11 April 2023 at 8:50am
|
|
Director Retirement & Appendix 3Z
|
30 March 2023 at 10:25am
|
|
Notice under Section 708A - Cleansing Notice
|
23 March 2023 at 2:40pm
|
|
Notification regarding unquoted securities - LBT
|
23 March 2023 at 2:35pm
|
|
Application for quotation of securities - LBT
|
23 March 2023 at 11:20am
|
|
Proposed issue of securities - LBT
|
20 March 2023 at 10:20am
|
|
Placement Supports APAS Pharma & EU Expansion
|
20 March 2023 at 10:15am
|
|
Half Yearly Report and Accounts
|
28 February 2023 at 11:55am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
23 January 2023 at 10:50am
|
|
LBT Company Presentation
|
20 January 2023 at 12:40pm
|
|
Quarterly Investor Call
|
19 January 2023 at 9:45am
|
|
Notification of cessation of securities - LBT
|
11 January 2023 at 9:05am
|
|
AstraZeneca Partners LBT for APAS Pharma Development
|
9 January 2023 at 9:10am
|
|
Release from Escrow
|
3 January 2023 at 10:25am
|
|
LBT Strengthens APAS Pharma Development
|
20 December 2022 at 9:20am
|
|
CCS Appoint Thermo Fisher as Exclusive European Distributor
|
19 December 2022 at 9:25am
|
|
Appendix 3Y - all Directors
|
2 December 2022 at 5:15pm
|
|
Notice under s708A - Cleansing Notice
|
28 November 2022 at 7:10pm
|
|
Notification regarding unquoted securities - LBT
|
28 November 2022 at 11:10am
|
|
Application for quotation of securities - LBT
|
28 November 2022 at 11:10am
|
|
Non-renounceable Rights Issue Results
|
28 November 2022 at 11:05am
|
|
Application for quotation of securities - LBT
|
25 November 2022 at 10:15am
|
|
Entitlement Offer Letters Mailed to Shareholders
|
1 November 2022 at 9:55am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 October 2022 at 9:45am
|
|
Application for quotation of securities - LBT
|
31 October 2022 at 9:25am
|
|
Application for quotation of securities - LBT
|
26 October 2022 at 3:50pm
|
|
Proposed issue of securities - LBT
|
26 October 2022 at 3:40pm
|
|
Results of Meeting
|
26 October 2022 at 3:25pm
|
|
Chair's Address to Shareholders
|
26 October 2022 at 12:35pm
|
|
CEO Presentation
|
26 October 2022 at 12:25pm
|
|
LBT Receives $1,206,058 R&D Tax Incentive
|
25 October 2022 at 4:30pm
|
|
Proposed issue of securities - LBT
|
25 October 2022 at 10:20am
|
|
Rights Issue Prospectus
|
25 October 2022 at 10:10am
|
|
Non-Renounceable Rights Issue
|
25 October 2022 at 10:05am
|
|
$1.5M Funding Awarded for New APAS Instrument
|
24 October 2022 at 10:20am
|
|
Notification of cessation of securities - LBT
|
17 October 2022 at 8:45am
|
|
Notice of Annual General Meeting/Proxy Form
|
21 September 2022 at 2:15pm
|
|
BioPhorum Presentation
|
14 September 2022 at 9:20am
|
|
APAS Independence Market Update
|
13 September 2022 at 9:50am
|
LBT Innovations